(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 26 July 2001 (26.07.2001)

PCT

(10) International Publication Number WO 01/53457 A3

(51) International Patent Classification⁷: 14/00, Λ61Κ 39/00, 43/00

C07K 5/00,

(21) International Application Number: PCT/US01/01665

(22) International Filing Date: 18 January 2001 (18.01.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 09/489,219

21 January 2000 (21.01.2000) US

(71) Applicant: UNIVERSITY OF CONNECTICUT HEALTH CENTER [US/US]; 263 Farmington Avenue, Farmington, CT 06030 (US).

(72) Inventor: SRIVASTAVA, Pramod, K.; 70 Pheasant Run, Avon, CT 06001 (US).

(74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (national): AU, CA, JP.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

- with international search report

(88) Date of publication of the international search report:
18 April 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINES AGAINST NEURODEGENERATIVE DISORDERS

(57) Abstract: The present invention relates to pharmaceutical compositions comprising antigenic molecules for use as vaccines for the treatment and prevention of neurodegenerative disorders and diseases, such as Alzheimer's Disease. The invention further relates to methods for the use of such pharmaceutical compositions as immunotherapeutic agents for treating and protecting against such neurodegenerative disorders and disease.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/01666

| A. CLASSIFICATION OF SUBJECT MATTER | | | | | |
|--|--|---|-------------------------------|--|--|
| IPC(7) :Co7K 5/00, 14/00; A61K 39/00, 45/00 US CL :530/300, 550; 424/1.11, 184.1 | | | | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | | |
| B. FIELDS SEARCHED | | | | | |
| Minimum documentation searched (classification system followed by classification symbols) | | | | | |
| U.S. : 530/500, 350; 424 | b/1.11, 184.1 | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields | | | | | |
| search | | - | | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) | | | | | |
| Medline, WEST | | | | | |
| | | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | |
| Category Citation of d | ocument, with indication, where a | ppropriate, of the relevant passages | Relevant to claim No. | | |
| | Cederbaum. J.M. A Phase I Study of Recombinant Human Ciliary Neurotrophic Factor (rHCNTF) in Patients with Amyotrophic Lateral 28, | | | | |
| 1 • | | | | | |
| l l | Sclerosis. Clinical Neuropharmacology. 1995. Vol. 18. No. 6. | | | | |
| pages 313-3. | pages 515-532, especially abstract. | | | | |
| Y Sanan. D.A. | Sanan, D.A. Apolipoprotein E Associates with Beta Amyloid Peptide | | | | |
| l l | of Alzheimer's Disease to Form Novel Monofibrils. J. Clin. Invest. | | | | |
| August 1994 | August 1994 Vol. 94. pages 860-869 | | | | |
| V I.D. M.I. | I D MI Delfante of Auril 2 and E Auril 2 | | | | |
| | LaDu M.J. Purification of Apolipoprotein E Attenuates Isoform Specific Binding to Beta Amyloid. J. of Biol. Chem. April 1995. | | | | |
| , - | Vol. 270. No. 16. pages 9039-42 | | | | |
| | F | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | 1 | | |
| X Further documents are listed in the continuation of Box C. See patent family annex. | | | | | |
| "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand | | | | | |
| "A" document defining the gen to be of particular relevan | eral state of the art which is not considered on | the principle or theory underlying the | | | |
| earties document hindinated on or sizes the international utiling date | | "X" document of particular relevance; the considered novel or cannot be consider | | | |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other | | "Y" document of particular relevance; the | e claimed invention sennet ha | | |
| special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other | | considered to involve an inventive step with one or more other such docum | when the document is combined | | |
| means | | obvious to a person skilled in the art | | | |
| "P" document published prior to the international filing date but later than the priority date claimed | | "A" document member of the same patent family | | | |
| Date of the actual completion of the international search Date of mailing of the international search report | | | | | |
| 19 JUNE 2001 | | 27 JUL 2 | 001 | | |
| Name and mailing address of the ISA/US Authorized officery | | | | | |
| Commissioner of Patents and Trademarks Box PCT SHARON L. TURNER | | | | | |
| Washington, D.C. 20231 Facsimile No. (703) 305-3230 Telephone No. (703) 308-0196 | | | | | |
| | | | | | |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/01665

| ategory* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No |
|----------|--|---------------------------------------|
| ategory | Citation of document, with indication, where appropriate, or the recent passages | i i i i i i i i i i i i i i i i i i i |
| | McGeer. P.L. Apolipoprotein E4(ApoE4) but not ApoE3 or ApoE2 potentiates Beta-amyloid protein activation of complement in vitro. Brain Research. 1997. Vol. 749. pages 135-138. | 1-33 |
| : | AL-SABBAGH. A.M. Decreased CNS Inflammation and Absence | 1-3, 5, 16, 26, 28 |
| | of Clinical Exacerbation of Disease After Six Months Oral | 1 00 |
| | Administration of Bovine Myelin in Diseased SJL/J Mice with Chronic Relapsing Experimental Autoimmune Encephalomyelitis. J. of Neuroscience Research. 1996. Vol. 45. pages 424-429 | 1-33 |
| (| US 5,739,109 A (GALPIN ET AL) 14 April 1998 (14-04-95), see | 1-3, 5, 16, 26, 28 |
| , | entire document, especially claims. | 1 00 |
| | | 1-33 |
| | US 5,811,243 (STRITTMATTER ET AL) 22 September 1998 (22- | 1-6, 16-20, 26, 28 |
| 7 | 09-98) columns 2-3. | 1-33 |
| | | 1-99 |
| • | US 5,780,587 A (POTTER) 14 July 1998 (14-07-98), columns 2-3. | 1-33 |
| | · | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | • |
| | | |
| | | |
| | | |